Butyric Acid

Butyric Acid

SCHEMBL1994703

CCCC(=O)O.c1ccccc1

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.87
HDAC3 O15379 1/20 0.87
HDAC1 Q13547 1/20 0.87
HDAC2 Q92769 1/20 0.87
HDAC8 Q9BY41 1/20 0.87
AKR1B1 P15121 1/20 0.55
GPR84 Q9NQS5 7/20 0.52
PPARG P37231 7/20 0.52
PPARD Q03181 7/20 0.52
PPARA Q07869 7/20 0.52
HDAC11 Q96DB2 5/20 0.52
TSHR P16473 4/20 0.52
PTPN1 P18031 3/20 0.52
ALDH1A1 P00352 2/20 0.52
TLR2 O60603 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
FABP4 P15090 2/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
SLC22A8 Q8TCC7 1/20 0.52
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL11626724 1.00 FFAR3 (0.87) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11626727 1.00 FFAR3 (0.87) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL31286426 1.00 FFAR3 (0.87) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11484161 0.97 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL28519333 0.97 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL9824028 0.94 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11042481 0.94 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11818808 0.94 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL28299248 0.94 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL27525465 0.94 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114349590-B Method for synthesizing aromatic compound 上海巽田科技股份有限公司 2024-01-30 CN claimed
CN-110392579-A Mouse myopia induction model and endoplasmic reticulum stress inhibitor for myopia prevention/inhibition 坪田实验室股份有限公司 2019-10-29 CN claimed
CN-110339181-A A kind of pH response type nano preparation and its preparation method and application based on click-reaction 中国药科大学 2019-10-18 CN claimed
CN-109010827-A Chlorambucil-poly-dopamine prodrug nanoparticle antitumor application thereof 上海交通大学 2018-12-18 CN claimed
CN-105289435-B A kind of preparation method of magnetism self-repairing microcapsule 中国船舶重工集团公司第七二五研究所 2018-10-23 CN claimed
CN-104812369-B Core-shell particle, method for producing same, and composition containing core-shell particle 心悦生医股份有限公司 2017-11-24 CN claimed
CN-104910045-B Triad fullerene derivate and preparation method and application 苏州大学 2017-08-01 CN claimed
CN-106554395-A A kind of long acting erythropoietin simulating peptide and its preparation method and application 天津药物研究院有限公司 2017-04-05 CN claimed
CN-105289435-A Preparation method of magnetic self-repairing microcapsules NO 725 RES INST CHINA CSIC 2016-02-03 CN claimed
CN-104910045-A Triad fullerene derivative and preparation method and application thereof UNIV SOOCHOW 2015-09-16 CN claimed
CN-102702838-B Micro-crack self-repairing microcapsule and preparation method thereof NO 725 RES INST CHINA CSIC 2013-11-20 CN claimed
CN-102702838-A Micro-crack self-repairing microcapsule and preparation method thereof NO 725 RES INST CHINA CSIC 2012-10-03 CN claimed
CN-102604469-A Latent self-repair microcapsule and preparation method thereof NO 725 RES INST CHINA CSIC 2012-07-25 CN claimed
CN-101633625-A Method for preparing R-beta-aminobenzene butyric acid derivative JIANGSU HENGRUI MEDICINE CO 2010-01-27 CN claimed
EP-1964836-A2 A process for the preparation of perindopril erbumine in alpha crystalline form IPCA Laboratories Limited (IN) 2008-09-03 EP claimed
US-20080183011-A1 Process for preparation of perindopril erbumine in alpha crystalline form IPCA LABORATORIES LIMITED 2008-07-31 US claimed
US-20050107350-A1 Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith PHARMACIA CORPORATION (US) 2005-05-19 US claimed
CN-116217585-B Podophyllotoxin/epipodophyllotoxin derivative, preparation method and application thereof 安徽工业大学 2025-05-27 CN disclosed
US-3933806-A Cephalosporin michael adducts ELI LILLY AND COMPANY (US) 1976-01-20 US disclosed
US-3932479-A BRONCHODILATOR, HYPOTENSIVE, ANTIULCER AMERICAN CYANAMID COMPANY (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107350-A1 Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith PTGS2, PTGES2, PTGS1 FFAR3 2833/4885HDAC3 2646/4885HDAC1 2989/4885
US-20080183011-A1 Process for preparation of perindopril erbumine in alpha crystalline form ACE, REN, ADH1C FFAR3 1282/4885HDAC3 816/4885HDAC1 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.